Sirius collaborates with Golden Helix to advance diagnostic pipeline

Sirius Genomics, a developer of companion diagnostics, and Golden Helix, a global leader in genetic analysis solutions, announced today a collaboration under which Golden Helix will apply its expertise and technologies in SNP and copy number variant analysis and predictive modeling to advance development of Sirius' diagnostic pipeline.

Under this agreement, Sirius and Golden Helix are working together to develop a diagnostic to identify individuals who respond favorably to Vasopressin and similar compounds used in the treatment of septic shock and related conditions.

Septic shock occurs when sepsis (a severe infection spread via the bloodstream, characterized by a whole-body inflammatory state) leads to life-threatening low blood pressure. According to the US CDC, septic shock is the 13th leading cause of death in the United States, and the number one cause of deaths in intensive care units. Though the standard of care for addressing septic shock is intravenous norepinephrine, the mortality rate from septic shock remains approximately 50%.

"Golden Helix is an ideal partner for Sirius Genomics' pipeline development, providing us with access to significant expertise in GWAS analysis and bioinformatics capabilities. The combination of our funding from the National Research Council of Canada and this partnership with Golden Helix enables us to focus our strengths in discovery and development on our pipeline of companion diagnostic programs, and focus on improving outcomes in critical care medicine," stated Chris Wagner, president and CEO of Sirius Genomics.

"Advances in genomic technologies are making personalized medicine a reality for many conditions," said Dr. Christophe Lambert, president and CEO of Golden Helix. "However, developing the molecular diagnostics that are fundamental to personalized medicine requires unique capabilities. Our partnership with Sirius brings those capabilities together, and we are excited about what will come of it."

Source:

SIRIUS GENOMICS INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered ECG model predicts heart disease risk with precision